{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:02:05Z","timestamp":1791302525325,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2013,7,28]],"date-time":"2013-07-28T00:00:00Z","timestamp":1374969600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1007\/s00432-013-1479-0","type":"journal-article","created":{"date-parts":[[2013,7,27]],"date-time":"2013-07-27T13:37:34Z","timestamp":1374932254000},"page":"1563-1568","source":"Crossref","is-referenced-by-count":5,"title":["The identification of a small but significant subset of patients still targetable with anti-HER2 inhibitors when affected by triple negative breast carcinoma"],"prefix":"10.1007","volume":"139","author":[{"given":"Eleonora","family":"Brunello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Bogina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Bria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Vergine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Zamboni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Pedron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Daniele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Furlanetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Carbognin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcella","family":"Marconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erminia","family":"Manfrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merdol","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampaolo","family":"Tortora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Molino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bharat","family":"Jasani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Beccari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Bonetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Chilosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Martignoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Brunelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,7,28]]},"reference":[{"key":"1479_CR1","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/modpathol.2010.200","volume":"24","author":"S Badve","year":"2011","unstructured":"Badve S, Dabbs DJ, Schnitt SJ, Baehner FL, Decker T et al (2011) Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol 24:157\u2013167","journal-title":"Mod Pathol"},{"key":"1479_CR2","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1309\/AJCPLN78ZQXEMNMA","volume":"131","author":"JM Bartlett","year":"2009","unstructured":"Bartlett JM, Ibrahim M, Jasani B, Morgan JM, Ellis I et al (2009) External quality assurance of HER2 FISH and ISH testing: 3\u00a0years of the UK national external quality assurance scheme. Am J Clin Pathol 131:106\u2013111","journal-title":"Am J Clin Pathol"},{"key":"1479_CR3","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1136\/jcp.2011.089847","volume":"64","author":"JM Bartlett","year":"2011","unstructured":"Bartlett JM, Starczynski J, Atkey N, Kay E, O\u2019Grady A et al (2011) HER2 testing in the UK: recommendations for breast and gastric in situ hybridisation methods. J Clin Pathol 64:649\u2013653","journal-title":"J Clin Pathol"},{"key":"1479_CR4","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1373\/clinchem.2010.160853","volume":"57","author":"KJ Bloom","year":"2011","unstructured":"Bloom KJ, Cote RJ (2011) Counterpoint: both immunohistochemistry and fluorescence in situ hybridization play important roles for HER2 evaluation. Clin Chem 57:983\u2013985","journal-title":"Clin Chem"},{"key":"1479_CR5","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1309\/MD79CDXN1D01E862","volume":"129","author":"M Brunelli","year":"2008","unstructured":"Brunelli M, Manfrin E, Martignoni G, Bersani S, Remo A et al (2008) HER-2\/neu assessment in breast cancer using the original FDA and new ASCO\/CAP guideline recommendations: impact on selecting patients for herceptin therapy. Am J Clin Pathol 129:907\u2013911","journal-title":"Am J Clin Pathol"},{"key":"1479_CR6","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1200\/JCO.2010.34.5579","volume":"30","author":"LA Carey","year":"2012","unstructured":"Carey LA, Rugo HS, Marcom PK, Mayer EL, Esteva FJ et al (2012) TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol 30:2615\u20132623","journal-title":"J Clin Oncol"},{"key":"1479_CR7","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1470-2045(07)70074-8","volume":"8","author":"S Cleator","year":"2007","unstructured":"Cleator S, Heller W, Coombes RC (2007) Triple-negative breast cancer: therapeutic options. Lancet Oncol 8:235\u2013244","journal-title":"Lancet Oncol"},{"key":"1479_CR8","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1200\/JCO.1999.17.9.2639","volume":"17","author":"MA Cobleigh","year":"1999","unstructured":"Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S et al (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639\u20132648","journal-title":"J Clin Oncol"},{"issue":"Suppl 6","key":"1479_CR9","doi-asserted-by":"crossref","first-page":"vi56","DOI":"10.1093\/annonc\/mds196","volume":"23","author":"J Crown","year":"2012","unstructured":"Crown J, O\u2019Shaughnessy J, Gullo G (2012) Emerging targeted therapies in triple-negative breast cancer. Ann Oncol 23(Suppl 6):vi56\u2013vi65","journal-title":"Ann Oncol"},{"key":"1479_CR10","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1503\/cmaj.061011","volume":"176","author":"N Dendukuri","year":"2007","unstructured":"Dendukuri N, Khetani K, McIsaac M, Brophy J (2007) Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis. CMAJ 176:1429\u20131434","journal-title":"CMAJ"},{"key":"1479_CR11","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/path.1313","volume":"199","author":"M Dowsett","year":"2003","unstructured":"Dowsett M, Bartlett J, Ellis IO, Salter J, Hills M et al (2003) Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. J Pathol 199:418\u2013423","journal-title":"J Pathol"},{"key":"1479_CR12","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1200\/JCO.2008.19.7939","volume":"27","author":"M Dowsett","year":"2009","unstructured":"Dowsett M, Procter M, McCaskill-Stevens W, de Azambuja E, Dafni U et al (2009) Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1\u00a0year of trastuzumab: the HERA Trial. J Clin Oncol 27:2962\u20132969","journal-title":"J Clin Oncol"},{"key":"1479_CR13","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1056\/NEJMra1001389","volume":"363","author":"WD Foulkes","year":"2010","unstructured":"Foulkes WD, Smith IE, Reis-Filho JS (2010) Triple-negative breast cancer. N Engl J Med 363:1938\u20131948","journal-title":"N Engl J Med"},{"key":"1479_CR14","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/annonc\/mds064","volume":"23","author":"M Iorfida","year":"2012","unstructured":"Iorfida M, Dellapasqua S, Bagnardi V, Cardillo A, Rotmensz N et al (2012) HER2-negative (1+) breast cancer with unfavorable prognostic features: to FISH or not to FISH? Ann Oncol 23:1371\u20131372","journal-title":"Ann Oncol"},{"key":"1479_CR15","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1056\/NEJMc0801440","volume":"358","author":"S Paik","year":"2008","unstructured":"Paik S, Kim C, Wolmark N (2008) HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med 358:1409\u20131411","journal-title":"N Engl J Med"},{"key":"1479_CR16","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1200\/JCO.2000.18.21.3651","volume":"18","author":"G Pauletti","year":"2000","unstructured":"Pauletti G, Dandekar S, Rong H, Ramos L, Peng H et al (2000) Assessment of methods for tissue-based detection of the HER-2\/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 18:3651\u20133664","journal-title":"J Clin Oncol"},{"key":"1479_CR17","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/PAI.0b013e31802ced25","volume":"15","author":"WC Powell","year":"2007","unstructured":"Powell WC, Hicks DG, Prescott N, Tarr SM, Laniauskas S et al (2007) A new rabbit monoclonal antibody (4B5) for the immunohistochemical (IHC) determination of the HER2 status in breast cancer: comparison with CB11, fluorescence in situ hybridization (FISH), and interlaboratory reproducibility. Appl Immunohistochem Mol Morphol 15:94\u2013102","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"1479_CR18","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/j.1365-2559.2007.02889.x","volume":"52","author":"JS Reis-Filho","year":"2008","unstructured":"Reis-Filho JS, Tutt AN (2008) Triple negative tumours: a critical review. Histopathology 52:108\u2013118","journal-title":"Histopathology"},{"key":"1479_CR19","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783\u2013792","journal-title":"N Engl J Med"},{"key":"1479_CR20","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1309\/AJCPATBZ2JFN1QQC","volume":"137","author":"J Starczynski","year":"2012","unstructured":"Starczynski J, Atkey N, Connelly Y, O\u2019Grady T, Campbell FM et al (2012) HER2 gene amplification in breast cancer: a rogues\u2019 gallery of challenging diagnostic cases: UKNEQAS interpretation guidelines and research recommendations. Am J Clin Pathol 137:595\u2013605","journal-title":"Am J Clin Pathol"},{"key":"1479_CR21","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/cncr.25580","volume":"117","author":"S Vranic","year":"2011","unstructured":"Vranic S, Teruya B, Repertinger S, Ulmer P, Hagenkord J, Gatalica Z (2011) Assessment of HER2 gene status in breast carcinomas with polysomy of chromosome 17. Cancer 117:48\u201353","journal-title":"Cancer"},{"key":"1479_CR22","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1136\/jcp.2007.054866","volume":"61","author":"RA Walker","year":"2008","unstructured":"Walker RA, Bartlett JM, Dowsett M, Ellis IO, Hanby AM et al (2008) HER2 testing in the UK: further update to recommendations. J Clin Pathol 61:818\u2013824","journal-title":"J Clin Pathol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-013-1479-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-013-1479-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-013-1479-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,19]],"date-time":"2019-07-19T20:35:49Z","timestamp":1563568549000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-013-1479-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,28]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["1479"],"URL":"https:\/\/doi.org\/10.1007\/s00432-013-1479-0","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,28]]}}}